Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial
Authors:
- Andrew SteinASAndrew Stein
- Joaquim BellmuntJBJoaquim Bellmunt
- Bernard EscudierBEBernard Escudier
- Dennis KimDKDennis Kim
- Sotirios G. StergiopoulosSSSotirios G. Stergiopoulos
- William MietlowskiWMWilliam Mietlowski
- Robert J. MotzerRMRobert J. Motzer
- 1 December 2013
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 64 (6) , 994-1002
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 studyEuropean Journal of Cancer, 2012
- Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunineEuropean Journal of Cancer, 2012
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trialsBJU International, 2011
- NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted TherapyJournal of the National Comprehensive Cancer Network, 2011
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinibAnnals of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000